Clinical Trials Directory

Trials / Completed

CompletedNCT01303809

Enhanced Recovery After Laparoscopic Sleeve Gastrectomy - a Randomised Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
106 (actual)
Sponsor
University of Auckland, New Zealand · Academic / Other
Sex
All
Age
20 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The investigators wish to standardise and optimise perioperative care for consecutive patients undergoing laparoscopic sleeve gastrectomy for weight loss. The investigators will compare patients under a standardised perioperative care program to patients who undergo routine perioperative in our hospital and determine whether patients who had optimised perioperative care went home earlier and had fewer complications.

Conditions

Interventions

TypeNameDescription
OTHEREnhanced Recovery After Surgey for Sleeve GastrectomyIntraoperative: 1. Pre-op carbohydrate loading 2. No pre-op GIK while NBM 3. Pre-medication 4. Dexamethasone 4mg as antiemetic, IV Paracetamol (first dose) Parecoxib 40mg 5. Ondansetron regularly for first 48 hours and Cyclizine, Droperidol or Scopaderm as rescue antiemetics 6. Fluid restriction 7. Standardised method of anaesthesia 8. Give 40ml 0.5% bupivacaine with adrenaline administered prior to placement of laparoscopic port sites 9. 10ml 0.75% ropivacaine diluted to 50ml with 0.9% normal saline solution administered to surgical site prior to procedure Postoperative: 1. Rescue PCA for up to 12 hours. Oxynorm 5mg for rescue pain. Oxycontin 20mg bd/prn postoperatively 2. Maintenance IV fluids (60ml/hr plasmalyte to be stopped 0800 day 1 post op). Clear oral fluids 2 hours post op. Bariatric free oral fluids morning of day 1 3. Post operative oxygenation 4. Incentive spirometry 5. Drains (e.g. IDC) removed in recovery 6. Full mobilisation 4-8 hours post op) 7. Early Follow up

Timeline

Start date
2011-05-01
Primary completion
2012-05-01
Completion
2012-05-01
First posted
2011-02-25
Last updated
2012-05-25

Locations

1 site across 1 country: New Zealand

Source: ClinicalTrials.gov record NCT01303809. Inclusion in this directory is not an endorsement.